Needham Reiterates Buy on Lyell Immunopharma, Maintains $44 Price Target

Benzinga · 1d ago
Needham analyst Gil Blum reiterates Lyell Immunopharma (NASDAQ:LYEL) with a Buy and maintains $44 price target.